newsfilter
← Latest News
Business Wire·

Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588

COR588 well-tolerated in all dose cohorts Human pharmacokinetics support once daily oral dosing Multiple ascending dose data expected in the second quarter of 2022 Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pionee